Trial NCT04796896
Publication Anderson E, N Engl J Med , 2022
Primary outcome on the report: Safety and reactogenicity of mRNA-1273 and to infer efficacy on the basis of the noninferiority of the serum antibody geometric mean concentrations and serologic responses among these children as compared with those among young adults.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.